ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0769

Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial

Daniela Sieghart1, Daniel Mrak1, Elisabeth Simader1, Selma Tobudic2, Helga Radner1, Peter Mandl3, Lisa Göschl1, Maximilian Koblischke4, Nikolaus Hommer5, Lukas Hartl6, Philipp Hofer7, Felix Kartnig1, Thomas Hummel1, Andreas Kerschbaumer3, Thomas Deimel3, Antonia Puchner1, Renate Thalhammer8, Andreas Zuckermann9, Karin Stiasny4, Thomas Perkmann8, Helmuth Haslacher8, Markus Zeitlinger5, Ursula Wiedermann10, Judith Aberle4, Daniel Aletaha11, Leonhard Heinz1 and Michael Bonelli1, 1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 2Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, 3Medical University of Vienna, Vienna, Austria, 4Center for Virology, Medical University of Vienna, Vienna, Austria, 5Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria, 6Division of Gastroenterology, Medical University of Vienna, Vienna, Austria, 7Department of Pathology, Medical University of Vienna, Vienna, Austria, 8Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, 9Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 10Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology & Immunology, Medical University Vienna, Vienna, Austria, 11Medical University Vienna, Wien, Austria

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, COVID-19, immunology, Infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Patients under immunosuppressive therapy have a high risk for severe COVID-19 disease courses. However, efficacy of vaccination and therefore the right vaccination strategy remains unclear particularly in these individuals at risk.

The aim of the study was to investigate the efficacy of safety of a COVID-19 booster vaccination comparing homologous versus heterologous vaccination strategies in patients who did not seroconvert upon primary vaccination with an mRNA-based vaccine.

Methods: 75 patients under immunosuppressive treatment who received two doses of an mRNA vaccine with either BNT162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) were screened. 51 patients without humoral immune response were randomized and of those 46 received a third dose of either the same mRNA or the vector vaccine ChAdOx1 nCoV-19 (Oxford-AstraZeneca). In this blinded clinical trial, the primary endpoint was defined as the difference in the SARS-CoV-2 antibody seroconversion rate four weeks after an additional booster vaccination with a heterologous (vector) versus homologous (mRNA) vaccine. Further endpoints included the overall seroconversion rate and cellular immune response; safety was evaluated until week four. SARS-CoV-2-specific T-cell responses were determined by ELISpot assay in patients and healthy controls. A paper-based patient diary was used to evaluate adverse events within the first week after vaccination.

Results: Seroconversion rates at week four were higher in the mRNA (15/24 patients, 63%) as compared to the vector vaccine groups (4/22 patients, 18%; p=0.006). Overall, 41% of patients seroconverted after an additional booster vaccination. SARS-CoV-2-specific T-cell responses were similarly increased after a third dose of either vector or mRNA vaccine. In a multivariable logistic regression analysis, patient age and vaccine type were associated with seroconversion. No serious adverse event was attributed to COVID-19 booster vaccination.

Conclusion: Homologous SARS-CoV-2 vaccination was found to be superior to a heterologous vaccination regimen and should be applied in non-seroconverted patients under immunosuppression.


Disclosures: D. Sieghart, None; D. Mrak, Pfizer; E. Simader, Boehringer-Ingelheim; S. Tobudic, None; H. Radner, None; P. Mandl, None; L. Göschl, None; M. Koblischke, None; N. Hommer, None; L. Hartl, None; P. Hofer, None; F. Kartnig, Boehringer-Ingelheim, Eli Lilly; T. Hummel, None; A. Kerschbaumer, AbbVie/Abbott, Eli Lilly, Gilead, Merck/MSD, Amgen, Janssen, UCB; T. Deimel, None; A. Puchner, None; R. Thalhammer, None; A. Zuckermann, None; K. Stiasny, Pfizer; T. Perkmann, None; H. Haslacher, Glock Health, BlueSky Immunotherapies, Neutrolis; M. Zeitlinger, None; U. Wiedermann, None; J. Aberle, None; D. Aletaha, Novartis, SoBi, Sanofi, Amgen, Lilly, Merck, Pfizer, Roche, Sandoz, Janssen, AbbVie; L. Heinz, None; M. Bonelli, Eli Lilly.

To cite this abstract in AMA style:

Sieghart D, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Koblischke M, Hommer N, Hartl L, Hofer P, Kartnig F, Hummel T, Kerschbaumer A, Deimel T, Puchner A, Thalhammer R, Zuckermann A, Stiasny K, Perkmann T, Haslacher H, Zeitlinger M, Wiedermann U, Aberle J, Aletaha D, Heinz L, Bonelli M. Heterologous Vector versus Homologous mRNA COVID-19 Booster Vaccination in Non-seroconverted Immunosuppressed Patients: A Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/heterologous-vector-versus-homologous-mrna-covid-19-booster-vaccination-in-non-seroconverted-immunosuppressed-patients-a-randomized-controlled-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/heterologous-vector-versus-homologous-mrna-covid-19-booster-vaccination-in-non-seroconverted-immunosuppressed-patients-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology